NORCROSS,SpectRx has received a $1.4 million grant from the National Cancer Institute for development of its non-invasive cervical cancer detection device.
Cervical cancer is the third most common cancer among women around the world, causing some 233,000 deaths.
The grant will be used to help fund clinical trials necessary for the device to receive FDA approval, the company said. The tests are expected to begin within 90 days.
The SpectRx device utilizes biophotonic technology to identify cancers and precancers by analyzing light reflected from the cervix. No tissue sample is required.
SpectRx.com www.spectrx.com
